Geode Capital Management
NAGE

Geode Capital Management’s Niagen Bioscience NAGE Stock Holding History

Geode Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.93M Buy
1,344,921
+50,058
+4% +$270K ﹤0.01% 2658
2025
Q4 		$8.24M Sell
1,294,863
-604
-0% -$4.2K ﹤0.01% 2503
2025
Q3 		$12.1M Sell
1,295,467
-18
-0% -$182 ﹤0.01% 2309
2025
Q2 		$18.7M Buy
1,295,485
+116,268
+10% +$1.15M ﹤0.01% 1998
2025
Q1 		$8.14M Buy
1,179,217
+24,439
+2% +$154K ﹤0.01% 2417
2024
Q4 		$6.13M Buy
1,154,778
+5,186
+0.5% +$28.4K ﹤0.01% 2645
2024
Q3 		$4.2M Buy
1,149,592
+17,963
+2% +$56.5K ﹤0.01% 2850
2024
Q2 		$3.09M Buy
1,131,629
+570,570
+102% +$1.91M ﹤0.01% 2969
2024
Q1 		$1.95M Buy
561,059
+57,116
+11% +$106K ﹤0.01% 3118
2023
Q4 		$721K Hold
503,943
– – ﹤0.01% 3469
2023
Q3 		$736K Sell
503,943
-20,456
-4% -$31.9K ﹤0.01% 3448
2023
Q2 		$823K Sell
524,399
-33,036
-6% -$49.3K ﹤0.01% 3430
2023
Q1 		$853K Sell
557,435
-1,414
-0.3% -$2.52K ﹤0.01% 3414
2022
Q4 		$938K Buy
558,849
+5,524
+1% +$8.76K ﹤0.01% 3374
2022
Q3 		$680K Buy
553,325
+4,588
+0.8% +$7.38K ﹤0.01% 3574
2022
Q2 		$916K Sell
548,737
-375,326
-41% -$734K ﹤0.01% 3467
2022
Q1 		$2.27M Buy
924,063
+42,795
+5% +$117K ﹤0.01% 3199
2021
Q4 		$3.29M Buy
881,268
+17,054
+2% +$92.1K ﹤0.01% 3123
2021
Q3 		$5.42M Buy
864,214
+43,482
+5% +$358K ﹤0.01% 2866
2021
Q2 		$8.09M Buy
820,732
+84,995
+12% +$741K ﹤0.01% 2612
2021
Q1 		$6.87M Buy
735,737
+79,312
+12% +$629K ﹤0.01% 2620
2020
Q4 		$3.15M Buy
656,425
+26,589
+4% +$130K ﹤0.01% 2842
2020
Q3 		$2.52M Buy
629,836
+16,854
+3% +$81.3K ﹤0.01% 2754
2020
Q2 		$2.81M Buy
612,982
+25,350
+4% +$113K ﹤0.01% 2659
2020
Q1 		$1.92M Buy
587,632
+88,699
+18% +$341K ﹤0.01% 2692
2019
Q4 		$2.15M Buy
498,933
+65,762
+15% +$234K ﹤0.01% 2957
2019
Q3 		$1.7M Buy
433,171
+15,216
+4% +$64.9K ﹤0.01% 3024
2019
Q2 		$1.94M Buy
417,955
+38,320
+10% +$163K ﹤0.01% 2975
2019
Q1 		$1.59M Buy
379,635
+32,912
+9% +$119K ﹤0.01% 2980
2018
Q4 		$1.19M Buy
346,723
+17,361
+5% +$60.3K ﹤0.01% 3033
2018
Q3 		$1.41M Buy
329,362
+34,123
+12% +$147K ﹤0.01% 3073
2018
Q2 		$1.09M Buy
295,239
+119,802
+68% +$455K ﹤0.01% 3149
2018
Q1 		$736K Hold
175,437
– – ﹤0.01% 3263
2017
Q4 		$1.03M Hold
175,437
– – ﹤0.01% 3083
2017
Q3 		$754K Buy
175,437
+8,738
+5% +$31.9K ﹤0.01% 3219
2017
Q2 		$636K Sell
166,699
-27,605
-14% -$87.4K ﹤0.01% 3274
2017
Q1 		$522K Buy
194,304
+6,506
+3% +$18.4K ﹤0.01% 3300
2016
Q4 		$621K Buy
187,798
+12,395
+7% +$33.7K ﹤0.01% 3193
2016
Q3 		$522K Buy
175,403
+3,033
+2% +$11.1K ﹤0.01% 3229
2016
Q2 		$713K Buy
+172,370
New +$815K ﹤0.01% 3060

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management's NAGE Position: Q1 2026 in Review

Geode Capital Management increased its Niagen Bioscience (NAGE) stake by 3.9% in Q1 2026, buying an estimated $270K and bringing the position to 1,344,921 shares worth $5.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2658.

Geode Capital Management first reported a position in NAGE in Q2 2016 and has held it in 40 quarters since. The position peaked at $18.7M in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Geode Capital Management held 1,344,921 shares of Niagen Bioscience worth $5.93M as of Q1 2026.
  • Geode Capital Management bought 50,058 Niagen Bioscience shares in Q1 2026, an estimated $270K.
  • Niagen Bioscience made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2658 holding.
  • Geode Capital Management first reported a position in Niagen Bioscience in Q2 2016 and has held it in 40 quarters since.
  • Geode Capital Management's Niagen Bioscience position peaked at $18.7M in Q2 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.